Research ExplorerPublicationsCost per responder analysis of ustekinumab and etanercept fo...

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.

Standard

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. / Martin, Silas; Feldman, Steven R; Augustin, Matthias; Szapary, Philippe; Schenkel, Brad.

In: J DERMATOL TREAT, Vol. 22, No. 3, 3, 2011, p. 138-143.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Martin, S, Feldman, SR, Augustin, M, Szapary, P & Schenkel, B 2011, 'Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.', J DERMATOL TREAT, vol. 22, no. 3, 3, pp. 138-143. <http://www.ncbi.nlm.nih.gov/pubmed/21254886?dopt=Citation>

APA

Martin, S., Feldman, S. R., Augustin, M., Szapary, P., & Schenkel, B. (2011). Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J DERMATOL TREAT, 22(3), 138-143. [3]. http://www.ncbi.nlm.nih.gov/pubmed/21254886?dopt=Citation

Vancouver

Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J DERMATOL TREAT. 2011;22(3):138-143. 3.

Bibtex

@article{e058ca02229a41888fb5aa41779a4fa9,
title = "Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.",
abstract = "To compare the cost per responder of ustekinumab with etanercept based on data from the active comparator ACCEPT trial.",
keywords = "Humans, Antibodies, Monoclonal/*economics/therapeutic use, *Drug Costs, Endpoint Determination, Immunoglobulin G/*economics/therapeutic use, Psoriasis/*drug therapy/economics, Receptors, Tumor Necrosis Factor/therapeutic use, Humans, Antibodies, Monoclonal/*economics/therapeutic use, *Drug Costs, Endpoint Determination, Immunoglobulin G/*economics/therapeutic use, Psoriasis/*drug therapy/economics, Receptors, Tumor Necrosis Factor/therapeutic use",
author = "Silas Martin and Feldman, {Steven R} and Matthias Augustin and Philippe Szapary and Brad Schenkel",
year = "2011",
language = "English",
volume = "22",
pages = "138--143",
journal = "J DERMATOL TREAT",
issn = "0954-6634",
publisher = "informa healthcare",
number = "3",

}

RIS

TY - JOUR

T1 - Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.

AU - Martin, Silas

AU - Feldman, Steven R

AU - Augustin, Matthias

AU - Szapary, Philippe

AU - Schenkel, Brad

PY - 2011

Y1 - 2011

N2 - To compare the cost per responder of ustekinumab with etanercept based on data from the active comparator ACCEPT trial.

AB - To compare the cost per responder of ustekinumab with etanercept based on data from the active comparator ACCEPT trial.

KW - Humans

KW - Antibodies, Monoclonal/economics/therapeutic use

KW - Drug Costs

KW - Endpoint Determination

KW - Immunoglobulin G/economics/therapeutic use

KW - Psoriasis/drug therapy/economics

KW - Receptors, Tumor Necrosis Factor/therapeutic use

KW - Humans

KW - Antibodies, Monoclonal/economics/therapeutic use

KW - Drug Costs

KW - Endpoint Determination

KW - Immunoglobulin G/economics/therapeutic use

KW - Psoriasis/drug therapy/economics

KW - Receptors, Tumor Necrosis Factor/therapeutic use

M3 - SCORING: Journal article

VL - 22

SP - 138

EP - 143

JO - J DERMATOL TREAT

JF - J DERMATOL TREAT

SN - 0954-6634

IS - 3

M1 - 3

ER -